Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 2006

View Archived Issues

Icatibant studied in angioedema patients and healthy volunteers

Studies assess reversal of neuromuscular block with sugammadex

Casopitant reduces postoperative vomiting in opioid-treated patients

Atiprimod inhibits Jak-STAT signaling, abrogates AML cell growth

Canadian clearance for phase I study of PRX-302 in BPH

Newron grants Serono rights to safinamide in cognitive disorders

CAT and Debiopharm sign agreement for SC-1 for gastric cancer

Approvable letter for extended dosing of Aranesp

NNZ-2591 reverses memory loss in preclinical study

Positive preclinical results for PLX-I

Hana acquires rights to menadione

ProtoKinetix reports recent findings with AAGP

Roche to collaborate on InterMune's HCV protease inhibitor program

Arbor Vita and NoNO collaborate on novel treatment for stroke

European CHMP gives advice on phase III plan for naproxcinod

Benitec licenses ddRNAi technology to Tacere Therapeutics

Lilly to acquire ICOS

Genzyme and AnorMED reach agreement on acquisition

Taxotere approved for head and neck cancer

Yallaferon approved in China for cervicitis

Zolinza launched for cutaneous manifestations in CTCL

Novel agents for treating endocrine-related disorders disclosed in recent patent literature

New antiarthritic agents disclosed in recent patents

SCH-747123 displays good BACE1 inhibiting profile in vitro and in vivo

Ipsen present the broad therapeutic potential of BN-83026 in neurodegenerative diseases

Abbott reports on a novel alpha7 nAChR agonist that provides cognitive enhancement

Neuroprotective effects of the new JNK inhibitor ER-181304

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...